Literature DB >> 29338639

Is Continuous Passive Motion Effective in Patients with Lymphedema? A Randomized Controlled Trial.

Ramazan Kizil1, Banu Dilek1, Ebru Şahin1, Onur Engin1, Ali Can Soylu1, Elif Akalin1, Serap Alper1.   

Abstract

BACKGROUND: In this randomized controlled study, we aimed to evaluate the effect of shoulder flexion exercise using continuous passive motion (CPM) on lymphedema during the treatment of breast cancer-related lymphedema (BCRL).
METHODS: Thirty patients with BCRL were enrolled and completed the study. Fourteen patients were treated with complete decongestive therapy (CDT) and CPM in the intervention group, and 16 patients were treated with CDT alone (control group) for 15 sessions. The main outcome measures were included; the shoulder range of motion (ROM) assessed with a goniometer, limb volume difference measured using the water immersion method, function with the Disabilities of the Arm, Shoulder and Hand (DASH), and the quality of life using the Functional Assessment of Cancer Therapy for Breast Cancer (FACT-B4). Lymphedema volume measures were taken at baseline, on days 1, 2, 3, 4, 5, 10, and 15; and shoulder ROM, FACT-B4, and DASH were taken at baseline and on day 15.
RESULTS: All subjects were similar at baseline. After treatment significant improvement was found in ROM, volumetric differences, DASH, and FACT-B4 scores in both groups. No significant differences were observed in the volumetric differences, ROM, and the DASH, and FACT-B4 scores between the groups, except for the FACT-B4 physical well-being subscores, which were better in intervention group.
CONCLUSION: Our study results showed that CPM did not contribute to the reduction of BCRL.

Entities:  

Keywords:  continuous passive motion; function; lymphedema; quality of life

Mesh:

Year:  2018        PMID: 29338639     DOI: 10.1089/lrb.2017.0018

Source DB:  PubMed          Journal:  Lymphat Res Biol        ISSN: 1539-6851            Impact factor:   2.589


  3 in total

1.  Activity-Oriented Antiedema Proprioceptive Therapy (TAPA) for Shoulder Mobility Improvement in Women with Upper Limb Lymphedema Secondary to Breast Cancer: A Multicenter Controlled Clinical Trial.

Authors:  María Nieves Muñoz-Alcaraz; Antonio José Jiménez-Vílchez; Mirian Santamaría-Peláez; Luis A Pérula-de Torres; María Victoria Olmo-Carmona; María Teresa Muñoz-García; Presentación Jorge-Gutiérrez; Jesús Serrano-Merino; Esperanza Romero-Rodríguez; Lorena Rodríguez-Elena; Raquel Refusta-Ainaga; María Pilar Lahoz-Sánchez; Belén Miró-Palacios; Mayra Medrano-Cid; Rosa Magallón-Botaya; Luis A Mínguez-Mínguez; Josefa González-Santos; Jerónimo J González-Bernal
Journal:  J Clin Med       Date:  2022-04-16       Impact factor: 4.964

2.  Efficacy and efficiency of a new therapeutic approach based on activity-oriented proprioceptive antiedema therapy (TAPA) for edema reduction and improved occupational performance in the rehabilitation of breast cancer-related arm lymphedema in women: a controlled, randomized clinical trial.

Authors:  María Nieves Muñoz-Alcaraz; Luis Ángel Pérula-de-Torres; Jesús Serrano-Merino; Antonio José Jiménez-Vílchez; María Victoria Olmo-Carmona; María Teresa Muñoz-García; Cruz Bartolomé-Moreno; Bárbara Oliván-Blázquez; Rosa Magallón-Botaya
Journal:  BMC Cancer       Date:  2020-11-09       Impact factor: 4.430

3.  Impact of Activity-Oriented Propioceptive Antiedema Therapy on the Health-Related Quality of Life of Women with Upper-Limb Lymphedema Secondary to Breast Cancer-A Randomized Clinical Trial.

Authors:  María Nieves Muñoz-Alcaraz; Luis A Pérula-de Torres; Antonio José Jiménez-Vílchez; Paula Rodríguez-Fernández; María Victoria Olmo-Carmona; María Teresa Muñoz-García; Presentación Jorge-Gutiérrez; Jesús Serrano-Merino; Esperanza Romero-Rodríguez; Lorena Rodríguez-Elena; Raquel Refusta-Ainaga; María Pilar Lahoz-Sánchez; Belén Miró-Palacios; Mayra Medrano-Cid; Rosa Magallón-Botaya; Mirian Santamaría-Peláez; Luis A Mínguez-Mínguez; Jerónimo J González-Bernal
Journal:  J Clin Med       Date:  2022-03-28       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.